Equities research analysts expect Emergent Biosolutions Inc (NYSE:EBS) to post earnings of $0.51 per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Emergent Biosolutions’ earnings, with estimates ranging from $0.35 to $0.59. Emergent Biosolutions reported earnings per share of $0.73 in the same quarter last year, which would suggest a negative year-over-year growth rate of 30.1%. The firm is scheduled to issue its next earnings results on Thursday, November 1st.
According to Zacks, analysts expect that Emergent Biosolutions will report full year earnings of $2.33 per share for the current financial year, with EPS estimates ranging from $2.15 to $2.48. For the next year, analysts expect that the business will report earnings of $2.83 per share, with EPS estimates ranging from $2.18 to $3.59. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow Emergent Biosolutions.
Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported $1.07 EPS for the quarter, topping the consensus estimate of $0.88 by $0.19. Emergent Biosolutions had a net margin of 16.55% and a return on equity of 15.09%. The firm had revenue of $220.20 million during the quarter, compared to analyst estimates of $208.94 million. During the same quarter in the prior year, the business posted $0.13 earnings per share. Emergent Biosolutions’s revenue for the quarter was up 118.5% compared to the same quarter last year.
Several research firms have recently issued reports on EBS. Wells Fargo & Co set a $61.00 price objective on shares of Emergent Biosolutions and gave the stock a “hold” rating in a research report on Friday. Chardan Capital increased their price objective on shares of Emergent Biosolutions from $53.00 to $57.00 and gave the stock a “buy” rating in a research report on Friday, August 3rd. Cantor Fitzgerald reissued a “buy” rating and issued a $62.00 price objective on shares of Emergent Biosolutions in a research report on Thursday, August 2nd. Zacks Investment Research raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating and set a $60.00 price objective for the company in a research report on Tuesday, July 10th. Finally, Argus began coverage on shares of Emergent Biosolutions in a research report on Wednesday, June 13th. They issued a “buy” rating and a $62.00 price objective for the company. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $59.57.
In other news, CEO Daniel Abdun-Nabi sold 15,785 shares of the company’s stock in a transaction on Tuesday, June 5th. The shares were sold at an average price of $52.11, for a total value of $822,556.35. Following the completion of the transaction, the chief executive officer now directly owns 197,343 shares in the company, valued at $10,283,543.73. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Fuad El-Hibri sold 15,000 shares of the company’s stock in a transaction on Monday, July 9th. The shares were sold at an average price of $53.61, for a total transaction of $804,150.00. Following the completion of the transaction, the chairman now owns 1,539,993 shares of the company’s stock, valued at $82,559,024.73. The disclosure for this sale can be found here. Insiders sold 52,538 shares of company stock valued at $2,798,946 in the last three months. Company insiders own 16.50% of the company’s stock.
Several hedge funds have recently made changes to their positions in EBS. Two Sigma Investments LP purchased a new position in shares of Emergent Biosolutions in the fourth quarter valued at $223,000. Teachers Advisors LLC boosted its stake in Emergent Biosolutions by 2.4% during the 4th quarter. Teachers Advisors LLC now owns 61,415 shares of the biopharmaceutical company’s stock valued at $2,854,000 after acquiring an additional 1,462 shares during the last quarter. MetLife Investment Advisors LLC bought a new position in Emergent Biosolutions during the 4th quarter valued at $730,000. Xact Kapitalforvaltning AB bought a new position in Emergent Biosolutions during the 4th quarter valued at $265,000. Finally, FDx Advisors Inc. boosted its stake in Emergent Biosolutions by 83.0% during the 1st quarter. FDx Advisors Inc. now owns 24,786 shares of the biopharmaceutical company’s stock valued at $1,305,000 after acquiring an additional 11,245 shares during the last quarter. Institutional investors and hedge funds own 82.65% of the company’s stock.
Shares of Emergent Biosolutions traded down $1.43, hitting $55.03, during trading hours on Friday, Marketbeat reports. The company’s stock had a trading volume of 300,839 shares, compared to its average volume of 249,817. Emergent Biosolutions has a 1-year low of $32.48 and a 1-year high of $60.00. The firm has a market capitalization of $2.82 billion, a P/E ratio of 28.96, a PEG ratio of 1.21 and a beta of 1.20. The company has a quick ratio of 4.15, a current ratio of 5.59 and a debt-to-equity ratio of 0.01.
About Emergent Biosolutions
Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.
See Also: Diversification in Your Portfolio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.